The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | The evolving role of autoSCT in myeloma and moving immunotherapies into earlier treatment lines
Angelo Maiolino, MD, PhD, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, comments on the evolving role of autologous stem cell transplantation (autoSCT) in the treatment of multiple myeloma, noting that bispecifics and CAR-T are emerging as promising options for earlier lines of therapy. Prof. Maiolino mentions that teclistamab and ciltacabtagene autoleucel have shown promise in first-line treatment. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The key messages are the AST, the autologous stem cell transplantations, still now is a backbone, an important backbone on the first line of multiple myeloma treatment. But the bispecifics and the CAR-T is moving to the early lines of therapy. There are preliminary data particularly concerning the bispecifics referring to the potential use in first line for AST eligible patients. I can say, for example, a presentation on ASH 2024, last year, with the address of the use of teclistamab in combination with daratumumab and lenalidomide, or teclistamab in combination with daratumumab, bortezomib, and lenalidomide...
The key messages are the AST, the autologous stem cell transplantations, still now is a backbone, an important backbone on the first line of multiple myeloma treatment. But the bispecifics and the CAR-T is moving to the early lines of therapy. There are preliminary data particularly concerning the bispecifics referring to the potential use in first line for AST eligible patients. I can say, for example, a presentation on ASH 2024, last year, with the address of the use of teclistamab in combination with daratumumab and lenalidomide, or teclistamab in combination with daratumumab, bortezomib, and lenalidomide. That’s a phase one, two study with few patients included, but the results are very impressive on this particular trial. with the large majority of the patients obtaining a complete response with this combination, and almost 100 patients obtaining MRD negative at the third cycle of induction. So there are studies, preliminary studies, that include the bispecifics. And again, it’s also for the CAR-T. The CAR-T, we have the data of the study CARTITUDE-4, the CARTITUDE-4 study. This study included patients from one to third line of therapy. And in this study, comparing it to a standard of care. and there are amazing results in these early lines of therapy with more than 60% of the patients reaching MRD negativity. So the CAR-T is also moving to the first line. The trial is the CARTITUDE-6 who compared a strategy with cilta-cel without autologous stem cell transplantation. So one arm with autologous stem cell transplantation and then another arm with a cilta-cel infusion after the induction. So maybe the CAR-T and the bispecifics both are moving to the first line of therapy and maybe the autologous stem cell transplantation will not in the future stay as a backbone first-line therapy. We don’t know. We need to wait for the final results of those studies. But it’s a probability.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
